JP2019534288A - デクスメデトミジン経皮送達デバイスを用いた疼痛管理の方法 - Google Patents

デクスメデトミジン経皮送達デバイスを用いた疼痛管理の方法 Download PDF

Info

Publication number
JP2019534288A
JP2019534288A JP2019522825A JP2019522825A JP2019534288A JP 2019534288 A JP2019534288 A JP 2019534288A JP 2019522825 A JP2019522825 A JP 2019522825A JP 2019522825 A JP2019522825 A JP 2019522825A JP 2019534288 A JP2019534288 A JP 2019534288A
Authority
JP
Japan
Prior art keywords
subject
dexmedetomidine
hours
delivery device
transdermal delivery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2019522825A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019534288A5 (enExample
Inventor
ゴンソルブス，ローズ・マリー
十太郎 首藤
十太郎 首藤
ソン，ワン−ニン
ファン，スティーヴン・シッピング
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teikoku Pharma USA Inc
Original Assignee
Teikoku Pharma USA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teikoku Pharma USA Inc filed Critical Teikoku Pharma USA Inc
Publication of JP2019534288A publication Critical patent/JP2019534288A/ja
Publication of JP2019534288A5 publication Critical patent/JP2019534288A5/ja
Priority to JP2022206760A priority Critical patent/JP2023036825A/ja
Priority to JP2025071090A priority patent/JP2025108704A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019522825A 2016-10-31 2017-10-31 デクスメデトミジン経皮送達デバイスを用いた疼痛管理の方法 Withdrawn JP2019534288A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022206760A JP2023036825A (ja) 2016-10-31 2022-12-23 デクスメデトミジン経皮送達デバイスを用いた疼痛管理の方法
JP2025071090A JP2025108704A (ja) 2016-10-31 2025-04-23 デクスメデトミジン経皮送達デバイスを用いた疼痛管理の方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662415248P 2016-10-31 2016-10-31
US62/415,248 2016-10-31
US201762547582P 2017-08-18 2017-08-18
US62/547,582 2017-08-18
PCT/US2017/059357 WO2018081812A2 (en) 2016-10-31 2017-10-31 Methods of managing pain using dexmedetomidine transdermal delivery devices

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022206760A Division JP2023036825A (ja) 2016-10-31 2022-12-23 デクスメデトミジン経皮送達デバイスを用いた疼痛管理の方法

Publications (2)

Publication Number Publication Date
JP2019534288A true JP2019534288A (ja) 2019-11-28
JP2019534288A5 JP2019534288A5 (enExample) 2020-04-23

Family

ID=62020311

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019522825A Withdrawn JP2019534288A (ja) 2016-10-31 2017-10-31 デクスメデトミジン経皮送達デバイスを用いた疼痛管理の方法
JP2022206760A Withdrawn JP2023036825A (ja) 2016-10-31 2022-12-23 デクスメデトミジン経皮送達デバイスを用いた疼痛管理の方法
JP2025071090A Pending JP2025108704A (ja) 2016-10-31 2025-04-23 デクスメデトミジン経皮送達デバイスを用いた疼痛管理の方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022206760A Withdrawn JP2023036825A (ja) 2016-10-31 2022-12-23 デクスメデトミジン経皮送達デバイスを用いた疼痛管理の方法
JP2025071090A Pending JP2025108704A (ja) 2016-10-31 2025-04-23 デクスメデトミジン経皮送達デバイスを用いた疼痛管理の方法

Country Status (10)

Country Link
US (1) US12527770B2 (enExample)
EP (1) EP3532038A4 (enExample)
JP (3) JP2019534288A (enExample)
KR (4) KR20210113439A (enExample)
CN (2) CN110022865A (enExample)
BR (1) BR112019006955A2 (enExample)
CA (1) CA3038354C (enExample)
RU (1) RU2723761C1 (enExample)
TW (1) TWI764951B (enExample)
WO (1) WO2018081812A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023036825A (ja) * 2016-10-31 2023-03-14 テイコク ファーマ ユーエスエー インコーポレーテッド デクスメデトミジン経皮送達デバイスを用いた疼痛管理の方法

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3338768T3 (pl) 2016-12-20 2020-05-18 Lts Lohmann Therapie-Systeme Ag Transdermalny system terapeutyczny zawierający asenapinę
ES3001152T3 (es) 2016-12-20 2025-03-04 Lts Lohmann Therapie Systeme Ag Sistema terapéutico transdérmico que contiene asenapina y polisiloxano o poliisobutileno
SG10202107367SA (en) 2016-12-31 2021-08-30 Bioxcel Therapeutics Inc Use of sublingual dexmedetomidine for the treatment of agitation
EP3810099A1 (en) * 2018-06-20 2021-04-28 LTS Lohmann Therapie-Systeme AG Transdermal therapeutic system containing asenapine
ES3004544T3 (en) 2018-06-27 2025-03-12 Bioxcel Therapeutics Inc Film formulations containing dexmedetomidine and methods of producing them
BR112021019190A2 (pt) * 2019-04-17 2021-11-30 Lts Lohmann Therapie Systeme Ag Sistema terapêutico transdérmico
US20240024288A1 (en) 2019-07-19 2024-01-25 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
WO2021026375A1 (en) * 2019-08-07 2021-02-11 Alkermes, Inc. Fused bicyclic compounds for the treatment of pain
WO2021026378A1 (en) * 2019-08-07 2021-02-11 Alkermes, Inc. Indole compounds for the treatment of pain
WO2021026377A1 (en) * 2019-08-07 2021-02-11 Alkermes, Inc. Lactam-containing compounds for the treatment of pain
WO2021026380A1 (en) * 2019-08-07 2021-02-11 Alkermes, Inc. Phenyltriazole compounds for the treatment of pain
CN111281850A (zh) * 2020-03-14 2020-06-16 周琛 止痛药物组合物及其用途
CN121987597A (zh) * 2021-11-11 2026-05-08 北京泰德制药股份有限公司 一种右美托咪定透皮贴剂及其制备方法和应用
CN117582424A (zh) * 2022-08-17 2024-02-23 宜昌人福药业有限责任公司 右美托咪定经皮组合物、透皮贴剂及其制备方法和应用
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
WO2025054340A1 (en) * 2023-09-05 2025-03-13 Teikoku Pharma Usa, Inc. Transdermal delivery patch for treating pain

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01294623A (ja) * 1988-02-29 1989-11-28 Farmos Yhtymae Oy ４‐置換イミダゾール誘導体を有効成分とする手術に際して使用する薬剤
JPH05503916A (ja) * 1989-08-18 1993-06-24 シグナス，インコーポレイテッド デキスメデトミジンを経皮的に投与する方法およびデバイス
JP2011524345A (ja) * 2008-06-04 2011-09-01 コーダ セラピューティクス， インコーポレイテッド ギャップジャンクション調節化合物を用いる疼痛の治療
JP2013516482A (ja) * 2010-01-08 2013-05-13 レクロ・ファーマ，インコーポレーテッド 局所経皮用デクスメデトミジン組成物およびそれらの使用方法
JP2014528474A (ja) * 2011-10-14 2014-10-27 ホスピーラ インコーポレイテッド デクスメデトミジンを用いて小児患者を治療する方法
WO2015093503A1 (ja) * 2013-12-18 2015-06-25 丸石製薬株式会社 含水型貼付剤
JP2016532645A (ja) * 2013-10-07 2016-10-20 テイコク ファーマ ユーエスエー インコーポレーテッド デクスメデトミジン経皮組成物を含む疼痛管理用方法及び組成物
JP2016532642A (ja) * 2013-10-07 2016-10-20 テイコク ファーマ ユーエスエー インコーポレーテッド デクスメデトミジン経皮送達デバイス及びその使用法

Family Cites Families (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2101114B (en) 1981-07-10 1985-05-22 Farmos Group Ltd Substituted imidazole derivatives and their preparation and use
JPS60163811A (ja) 1984-02-06 1985-08-26 Watanabe Yakuhin Kogyo Kk プロプラノロ−ル含有外用貼付剤
FI844786A0 (fi) 1984-12-04 1984-12-04 Farmos Oy Terapeutiskt utnyttjbar foerening.
FI864570A0 (fi) 1986-11-11 1986-11-11 Farmos Oy Terapeutiskt anvaendbar foerening.
GB2206880B (en) 1987-07-16 1991-04-24 Farmos Oy Optical isomers of an imidazole derivative
US5656286A (en) 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US4994267A (en) 1988-03-04 1991-02-19 Noven Pharmaceuticals, Inc. Transdermal acrylic multipolymer drug delivery system
US5217718A (en) 1989-08-18 1993-06-08 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
FI894911A0 (fi) 1989-10-17 1989-10-17 Farmos Oy En terapeutiskt vaerdefull foerening.
US5304569A (en) 1989-11-13 1994-04-19 Orion-Yhtyma Oy Compositions and their use in lowering intraocular pressure
US5447947A (en) 1990-02-26 1995-09-05 Arc 1 Compositions and methods of treatment of sympathetically maintained pain
US5070084A (en) 1990-02-26 1991-12-03 Campbell James N Treatment of sympathetically maintained pain
JP2849937B2 (ja) 1990-04-18 1999-01-27 日東電工株式会社 医療用貼付剤
GB9111732D0 (en) 1991-05-31 1991-07-24 Orion Yhtymae Oy The use of certain salts of medetomidine and its optically active enantiomers to regulate the rate of transdermal administration of the drugs
US5352456A (en) 1991-10-10 1994-10-04 Cygnus Therapeutic Systems Device for administering drug transdermally which provides an initial pulse of drug
AU2782592A (en) 1991-10-15 1993-05-21 Cygnus Therapeutic Systems Thermal enhancement of transdermal drug administration
US5459133A (en) 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
GB2281206A (en) 1993-08-25 1995-03-01 Orion Yhtymae Oy Use of dexmedetomidine
JPH0776526A (ja) 1993-09-06 1995-03-20 Sansei Seiyaku Kk 乳酸エステルを含有する経皮吸収製剤
JP2819236B2 (ja) 1994-05-06 1998-10-30 日東電工株式会社 経皮吸収製剤
GB2290964A (en) 1994-07-08 1996-01-17 Arto Olavi Urtti Transdermal drug delivery system
AU702593B2 (en) 1994-09-14 1999-02-25 Minnesota Mining And Manufacturing Company Matrix for transdermal drug delivery
US5635203A (en) 1994-09-29 1997-06-03 Alza Corporation Transdermal device having decreased delamination
WO2000023066A2 (en) 1998-10-20 2000-04-27 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain and inflammation
KR100333508B1 (ko) 1995-03-31 2002-07-18 타다시 마츠다 아크릴계용제형점착제의제조방법및의료용점착제
DK0836506T4 (da) 1995-06-07 2012-01-30 Ortho Mcneil Pharm Inc Transdermalt plaster til indgivelse af 17-deacetyl norgestimat alene eller i kombination med et østrogen
US5891461A (en) 1995-09-14 1999-04-06 Cygnus, Inc. Transdermal administration of olanzapine
GB9521680D0 (en) 1995-10-23 1996-01-03 Orion Yhtymo Oy New use of imidazole derivatives
US7150881B2 (en) 1997-06-26 2006-12-19 Mylan Technologies, Inc. Adhesive mixture for transdermal delivery of highly plasticizing drugs
ES2252865T3 (es) 1997-09-26 2006-05-16 Noven Pharmaceuticals, Inc. Composiciones bioadhesivas y metodos para la administracion topica de agentes activos.
US6329369B1 (en) 1997-12-04 2001-12-11 Allergan Sales, Inc. Methods of treating pain and other conditions
US20020102291A1 (en) 1997-12-15 2002-08-01 Noven Pharmaceuticals, Inc. Compositions and method for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate
US20020068754A1 (en) 1998-02-25 2002-06-06 Olney John W. Combination of adrenergic agonist and aryl-cyclo-alkanolamine for relieving chronic pain without adverse side effects
US20020016319A1 (en) 1998-02-25 2002-02-07 Olney John W. Combined adamantane derivative and adrenergic agonist for relief of chronic pain without adverse side effects
US20020177592A1 (en) 1998-02-25 2002-11-28 Olney John W. Combination of adrenergic agonist and tricyclo-alkylamine for relieving chronic pain without adverse side effects
AR015744A1 (es) 1998-04-01 2001-05-16 Orion Corp Uso de dexmedetomidina para sedacion en terapia intensiva
MXPA01003310A (es) 1998-10-02 2003-05-15 3M Innovative Properties Co Sistema de suministro de farmaco originados en mucosa y aplicaciones animales.
US7001609B1 (en) 1998-10-02 2006-02-21 Regents Of The University Of Minnesota Mucosal originated drug delivery systems and animal applications
US20030170195A1 (en) 2000-01-10 2003-09-11 Noven Pharmaceuticals, Inc. Compositions and methods for drug delivery
PE20001396A1 (es) 1999-01-18 2000-12-23 Gruenenthal Chemie Formulaciones medicamentosas retardadas que contienen una combinacion de un opioide o una sal fisiologicamente tolerables del mismo, un o-agonista
DE19918106A1 (de) 1999-04-22 2000-10-26 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit neutralisierten Acrylathaftklebern
GB9913677D0 (en) 1999-06-11 1999-08-11 Imperial College Formulation
DE19938823A1 (de) 1999-08-19 2001-02-22 Boehringer Ingelheim Pharma Medikamentöse Behandlung des Restless Leg Syndroms
AU4904101A (en) 1999-12-08 2001-07-09 Fluoro Probe, Inc. Method for relieving pain associated with an internal disease site
AU2001243414B2 (en) 2000-03-10 2005-05-19 Durect Corporation Opioid formulations
WO2001089448A2 (en) 2000-03-28 2001-11-29 Olney John W Combination of adrenergic agonist and nmda antagonist for relieving chronic pain without adverse side effects
US20050042194A1 (en) 2000-05-11 2005-02-24 A.P. Pharma, Inc. Semi-solid delivery vehicle and pharmaceutical compositions
EP1155617A1 (en) 2000-05-17 2001-11-21 Rockwool International A/S Mineral wool plant substrate
DE10138722C5 (de) 2000-08-17 2017-05-24 Schaeffler Technologies AG & Co. KG Antriebsstrang
US7635488B2 (en) 2001-03-13 2009-12-22 Dbv Technologies Patches and uses thereof
FR2822049B1 (fr) 2001-03-13 2003-08-01 Dbv Medica 1 Patch destine notamment a depister l'etat de sensibilisation d'un sujet a un allergene, procede de fabrication et utilisation
FR2832311B1 (fr) 2001-11-21 2004-04-16 Besins Int Belgique Poudre filmogene, compositions la comprenant, leurs procedes de preparation et leurs utilisations
AR033748A1 (es) * 2002-05-15 2004-01-07 Thalas Group Inc Un dispositivo para la administracion transdermica de sustancias farmacologicamente activas que comprende dos capas adhesivas superpuestas y un procedimiento para prepararlo
KR100511492B1 (ko) 2002-10-11 2005-08-31 주식회사 태평양 에페리손, 톨페리손 또는 그것들의 염을 포함하는경피흡수제제
EA200801731A1 (ru) 2003-01-23 2009-10-30 Шир Холдингз Аг Составы и способы лечения тробмоцитемии
DE10305137A1 (de) 2003-02-07 2004-08-26 Novosis Ag Transdermale therapeutische Abgabesysteme mit einem Butenolid
US20040214215A1 (en) 2003-03-07 2004-10-28 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
US7439241B2 (en) 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US20050059664A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Novel methods for identifying improved, non-sedating alpha-2 agonists
US20050020600A1 (en) 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
EP1652508B1 (en) 2003-07-31 2013-12-04 Hisamitsu Pharmaceutical Co., Inc. Adhesive patch
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
MXPA06002716A (es) 2003-09-12 2006-06-06 Allergan Inc Metodos y composiciones para el tratamiento de dolor y otras condiciones mediadas por adrenergicos de alfa-2.
US20050058696A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
UA84303C2 (ru) 2003-10-28 2008-10-10 Новен Фармасьютикалз, Инк. Система для трансдермальной доставки лечебного средства
CN101426502A (zh) 2004-05-25 2009-05-06 桑斯罗萨医药发展公司 治疗或预防炎症性皮肤疾病的化合物、制剂及方法
CA2580694A1 (en) 2004-09-23 2006-03-30 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
US20060166901A1 (en) 2005-01-03 2006-07-27 Yu Ruey J Compositions comprising O-acetylsalicyl derivatives of aminocarbohydrates and amino acids
US8114090B2 (en) 2005-01-06 2012-02-14 Kertzner Richard I Drill centering tool for removal of orthopedic plug
US20060210613A1 (en) 2005-03-15 2006-09-21 Carliss Richard D Therapeutic wound care product
WO2007035942A2 (en) 2005-09-23 2007-03-29 Alza Corporation Transdermal risperidone delivery system
EP2308480B1 (en) 2005-09-23 2014-08-13 ALZA Corporation High Enhancer-Loading Polyacrylate Formulation for Transdermal Applications
MX2008000486A (es) 2005-10-24 2008-03-07 Teikoku Pharma Usa Inc Composiciones topicas para el alivio del dolor de n-2,3-trimetil-2-isopropilbutamida y metodos para usar las mismas.
TWI389709B (zh) 2005-12-01 2013-03-21 Novartis Ag 經皮治療系統
CN1994290B (zh) 2006-01-04 2011-03-16 上海医药工业研究院 卡巴拉汀透皮贴剂及其制备方法
US7429575B2 (en) 2006-01-10 2008-09-30 Yu Ruey J N-(phosphonoalkyl)-amino acids, derivatives thereof and compositions and methods of use
KR101079914B1 (ko) 2006-01-27 2011-11-04 에프. 호프만-라 로슈 아게 중추신경계 장애를 위한 4-이미다졸 유도체의 용도
CA2643802A1 (en) 2006-02-27 2007-09-07 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
JP2009528382A (ja) 2006-03-01 2009-08-06 トリストラータ・インコーポレイテッド タール応答性皮膚疾患の局所治療のための組成物及び方法
GB0611241D0 (en) 2006-06-07 2006-07-19 Daniolabs Ltd The treatment of increased sebum production
WO2008032718A1 (en) 2006-09-11 2008-03-20 Sekisui Chemical Co., Ltd. Adhesive preparation
US20090098191A1 (en) 2007-10-16 2009-04-16 Anderson Christopher G Use of bases to stabilize transdermal formulations
EP3498299A1 (en) 2007-11-16 2019-06-19 Aclaris Therapeutics, Inc. Compositions and methods for treating purpura
US8011146B2 (en) 2007-12-19 2011-09-06 William Krause Blast-proof window and mullion system
WO2009124755A1 (en) 2008-04-08 2009-10-15 European Molecular Biology Laboratory (Embl) Compounds with novel medical uses and method of identifying such compounds
US8629172B2 (en) 2008-04-18 2014-01-14 Warsaw Orthopedic, Inc. Methods and compositions for treating post-operative pain comprising clonidine
WO2009139411A1 (ja) 2008-05-15 2009-11-19 久光製薬株式会社 パロノセトロンを含有する経皮吸収製剤
JP2011529490A (ja) 2008-07-28 2011-12-08 エンドジェンエックス， インコーポレイテッド アルファ−２アドレナリン受容体アゴニスト、および、エンドセリン受容体アンタゴニストを用いて疼痛を治療する方法
US20120156244A1 (en) 2008-08-01 2012-06-21 Alpha Synergy Development Inc. Nasal Compositions and Uses Thereof
US20110257188A1 (en) 2008-08-01 2011-10-20 Gerald Horn Compositions and methods for the treatment of nasal conditions
US20100197694A1 (en) 2008-08-01 2010-08-05 Gerald Horn Compositions and methods for treatment of diseases and conditions with increased vascular permeability
US20110244058A1 (en) 2008-08-01 2011-10-06 Gerald Horn Compositions and methods for treatment of pulmonary diseases and conditions
US20100202979A1 (en) 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of pulmonary diseases and conditions
EP2165706A1 (en) 2008-09-18 2010-03-24 BioAlliance Pharma Treating Inflammatory Pain in Mucosa of the Oral Cavity Using Mucosal Prolonged Release Bioadhesive Therapeutic Carriers.
US9308203B2 (en) 2008-10-01 2016-04-12 Taiwan Biotech Co., Ltd. Pressure sensitive adhesive matrix device or system for the treatment or prevention of onychomycosis or tinea pedis
JP5536661B2 (ja) 2008-10-30 2014-07-02 国立大学法人 岡山大学 局所麻酔用組成物
US20120095104A1 (en) 2008-11-30 2012-04-19 Oron Zachar Use of vasoconstrictors
EP2376073A2 (en) 2008-11-30 2011-10-19 Oron Zachar Dermal application of vasoconstrictors
US20100196286A1 (en) 2008-12-01 2010-08-05 Armer Thomas A Inhalation delivery methods and devices
FR2942138A1 (fr) 2009-02-16 2010-08-20 Galderma Res & Dev Association de composes pour le traitement ou la prevention des affections dermatologiques
JP2012158521A (ja) 2009-04-17 2012-08-23 Kureha Corp 外用剤
EP3305281A1 (en) 2009-05-15 2018-04-11 Recro Pharma, Inc. Sublingual dexmedetomidine compositions and methods of use thereof
US8410140B2 (en) 2009-06-01 2013-04-02 The Regents Of The University Of Michigan Anesthetic methods and compositions
CN102753532B (zh) 2009-12-09 2015-05-13 I-技术有限公司 美托咪定的制备方法
US9327105B2 (en) 2010-03-26 2016-05-03 Itrace Biomedical Inc. Active transdermal drug delivery system and the method thereof
CA2796280A1 (en) 2010-04-15 2011-10-20 The Royal Institution For The Advancement Of Learning / Mcgill Universit Y Topical treatments for pain
US9023788B2 (en) 2010-04-20 2015-05-05 New York University Methods compounds and pharmaceutical compositions for treating anxiety and mood disorders
US8563031B2 (en) 2010-05-27 2013-10-22 Absize, Inc. Piroxicam-containing matrix patches and methods for the topical treatment of acute and chronic pain and inflammation therewith
ES2528650T3 (es) 2010-11-17 2015-02-11 Hexal Ag Sistema terapéutico transdérmico que comprende buprenorfina
TWI433904B (zh) 2011-01-12 2014-04-11 Taiwan Biotech Co Ltd 多奈哌齊經皮貼片
US20120202864A1 (en) 2011-02-03 2012-08-09 Alpha Synergy Development Inc. Compositions and Methods for Treatment of Glaucoma
US20120309720A1 (en) 2011-02-03 2012-12-06 Alpha Synergy Development Inc. Compositions and methods for treatment of glaucoma
CN103501770B (zh) 2011-04-18 2015-04-29 久光制药株式会社 贴附剂的制造方法及贴附剂
CA2850277A1 (en) 2011-10-19 2013-04-25 Galderma S.A. Method for treating capillary hemangiomas
WO2013072763A2 (en) 2011-11-16 2013-05-23 Nometics Inc. Non-sensitizing transdermal clonidine patch
CA2858721C (en) 2011-12-11 2021-03-16 Recro Pharma, Inc. Intranasal dexmedetomidine compositions and methods of use thereof
US8242158B1 (en) 2012-01-04 2012-08-14 Hospira, Inc. Dexmedetomidine premix formulation
WO2013113690A1 (en) 2012-01-31 2013-08-08 Grünenthal GmbH Pharmaceutical patch for transdermal administration of (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4-b]indol]-4-amine
WO2013173317A1 (en) 2012-05-14 2013-11-21 Prospire, Llc TREATMENT OF OBSTRUCTIVE SLEEP APNEA WITH α2-ADRENERGIC RECEPTOR AGONISTS
CN110354267A (zh) 2012-08-31 2019-10-22 法尔麦兹公司 用于低血压复苏的方法和组合物
EP2919814A1 (en) 2012-11-13 2015-09-23 UCL Business Plc. Adrenergic agonists for use in treating liver damage
JP6370802B2 (ja) 2012-12-28 2018-08-08 テイコク ファーマ ユーエスエー インコーポレーテッド 持続性ブプレノルフィン経皮送達組成物およびそれの使用方法
EP3054934B1 (en) 2013-10-07 2024-05-22 Teikoku Pharma USA, Inc. Methods and compositions for treating withdrawal syndromes using non-sedative dexmedetomidine transdermal compositions
TWI709417B (zh) 2013-10-07 2020-11-11 美商帝國製藥美國股份有限公司 使用右美托咪啶經皮組成物用於治療注意力不足過動症、焦慮及失眠的方法及組成物
RU2648449C2 (ru) 2013-10-07 2018-03-26 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Способы и композиции для трансдермальной доставки неседативного количества дексмедетомидина
WO2016105449A1 (en) 2014-12-22 2016-06-30 Seth Lederman Compounds for use as pain therapeutics
KR20210113439A (ko) 2016-10-31 2021-09-15 테이코쿠 팔마 유에스에이, 인코포레이티드 덱스메데토미딘 경피 전달 장치를 이용한 통증을 관리하는 방법
TWI772807B (zh) 2019-05-27 2022-08-01 日商救急藥品工業股份有限公司 外用製劑
EP4364729A4 (en) 2021-08-23 2024-11-27 Yichang Humanwell Pharmaceutical Co., Ltd. TRANSDERMAL COMPOSITION OF DEXMEDETOMIDINE, TRANSDERMAL PATCH AND METHOD OF PREPARATION AND USE THEREOF
CN121987597A (zh) 2021-11-11 2026-05-08 北京泰德制药股份有限公司 一种右美托咪定透皮贴剂及其制备方法和应用
WO2025054340A1 (en) 2023-09-05 2025-03-13 Teikoku Pharma Usa, Inc. Transdermal delivery patch for treating pain

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01294623A (ja) * 1988-02-29 1989-11-28 Farmos Yhtymae Oy ４‐置換イミダゾール誘導体を有効成分とする手術に際して使用する薬剤
JPH05503916A (ja) * 1989-08-18 1993-06-24 シグナス，インコーポレイテッド デキスメデトミジンを経皮的に投与する方法およびデバイス
JP2011524345A (ja) * 2008-06-04 2011-09-01 コーダ セラピューティクス， インコーポレイテッド ギャップジャンクション調節化合物を用いる疼痛の治療
JP2013516482A (ja) * 2010-01-08 2013-05-13 レクロ・ファーマ，インコーポレーテッド 局所経皮用デクスメデトミジン組成物およびそれらの使用方法
JP2014528474A (ja) * 2011-10-14 2014-10-27 ホスピーラ インコーポレイテッド デクスメデトミジンを用いて小児患者を治療する方法
JP2016532645A (ja) * 2013-10-07 2016-10-20 テイコク ファーマ ユーエスエー インコーポレーテッド デクスメデトミジン経皮組成物を含む疼痛管理用方法及び組成物
JP2016532642A (ja) * 2013-10-07 2016-10-20 テイコク ファーマ ユーエスエー インコーポレーテッド デクスメデトミジン経皮送達デバイス及びその使用法
WO2015093503A1 (ja) * 2013-12-18 2015-06-25 丸石製薬株式会社 含水型貼付剤

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"神経障害性疼痛", ももたろう痛みのクリニック, JPN6023010314, 8 March 2023 (2023-03-08), JP, ISSN: 0005010072 *
日薬理誌, vol. 124, JPN6021049248, 2004, pages 171 - 179, ISSN: 0004861724 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023036825A (ja) * 2016-10-31 2023-03-14 テイコク ファーマ ユーエスエー インコーポレーテッド デクスメデトミジン経皮送達デバイスを用いた疼痛管理の方法
US12527770B2 (en) 2016-10-31 2026-01-20 Teikoku Pharma Usa, Inc. Methods of managing pain using dexmedetomidine transdermal delivery devices

Also Published As

Publication number Publication date
EP3532038A2 (en) 2019-09-04
WO2018081812A2 (en) 2018-05-03
TWI764951B (zh) 2022-05-21
CN121868263A (zh) 2026-04-17
JP2025108704A (ja) 2025-07-23
US20180117012A1 (en) 2018-05-03
KR20210113439A (ko) 2021-09-15
KR20250105683A (ko) 2025-07-08
RU2723761C1 (ru) 2020-06-17
BR112019006955A2 (pt) 2019-07-02
CN110022865A (zh) 2019-07-16
CA3038354A1 (en) 2018-05-03
TW201817419A (zh) 2018-05-16
JP2023036825A (ja) 2023-03-14
US12527770B2 (en) 2026-01-20
EP3532038A4 (en) 2020-06-03
WO2018081812A3 (en) 2019-01-17
KR20230048156A (ko) 2023-04-10
KR20190060007A (ko) 2019-05-31
CA3038354C (en) 2021-08-17

Similar Documents

Publication Publication Date Title
JP2023036825A (ja) デクスメデトミジン経皮送達デバイスを用いた疼痛管理の方法
TWI704933B (zh) 右美托咪啶經皮輸送裝置及使用其之方法
KR101891186B1 (ko) 덱스메데토미딘 경피 조성물을 포함하는 통증을 관리하기 위한 방법 및 조성물
JP6231670B2 (ja) 非鎮静性デクスメデトミジン経皮組成物を用いる、離脱症候群の治療法及び組成物
TWI629067B (zh) 用於經皮輸送非鎮靜量右美托咪啶之方法及組成物
US20250275930A1 (en) Transdermal delivery patch for treating pain
HK40010492A (en) Methods of managing pain using dexmedetomidine transdermal delivery devices
HK40018815A (en) Methods and compositions for managing pain comprising dexmedetomidine transdermal compositions
BR112016007327B1 (pt) Uso de dispositivo de distribuição transdérmica para controlar dor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191003

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200313

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200313

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210121

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210420

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210618

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210719

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211208

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220308

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220506

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220608

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220830

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221223

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20221223

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20230110

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230131

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230201

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230317

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20230322

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20240802